Sio Gene Therapies, Inc.

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new

Avrobio has announced that it is to halt all drug development in its gene therapy pipeline, and begin a “comprehensive exploration of strategic alternatives” to maximize shareholder value. The Cambri

Biotechnology valuations generally have been on the rise in recent months, relative to general stock market indices, but there still are a number of drug developers that are having trouble gaining tra

Adverum Biotechnologies, Inc. is the latest gene therapy player to feel the financial pinch but the US firm hopes a major restructuring will safeguard funds to advance its one-time wet age-related ma